{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:04:55Z","timestamp":1790172295106,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clml.2024.05.009","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:46:57Z","timestamp":1715600817000},"page":"e301-e313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5611-6115","authenticated-orcid":false,"given":"Jeff P.","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasiulla","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3231-0049","authenticated-orcid":false,"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Raz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Girardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel S.","family":"Krigsfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-5535","authenticated-orcid":false,"given":"Jacqueline C.","family":"Barrientos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.05.009_bib0001","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.009_bib0002","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2024.05.009_bib0003","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0004","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0006","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0007","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0008","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0009","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.05.009_bib0011","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2024.05.009_bib0012","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0013","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.05.009_bib0014","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.05.009_bib0015","series-title":"Presented at: 2021 ASH Meeting and Exposition","article-title":"Long-term results of alliance A041202 show continued advantage of Ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy","author":"Woyach","year":"2021"},{"key":"10.1016\/j.clml.2024.05.009_bib0016","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/10428194.2021.2020779","article-title":"Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies","volume":"63","author":"Burger","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.05.009_bib0017","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/asheducation-2018.1.248","article-title":"Relapsed CLL: sequencing, combinations, and novel agents","volume":"2018","author":"Brown","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2024.05.009_bib0018","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11899-020-00584-3","article-title":"Utilizing real-world evidence (RWE) to improve care in chronic lymphocytic leukemia: challenges and opportunities","volume":"15","author":"Islam","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2024.05.009_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2024.05.009_bib0020","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.009_bib0021","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.05.009_bib0022","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-133798","article-title":"Real-world prognostic biomarker testing, treatment patterns and dosing among 1461 patients (pts) with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) from the inform CLL prospective observational registry","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.009_bib0023","series-title":"Presented at: 2021 ASH Meeting and Exposition","article-title":"Application of National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for CLL\/SLL from the informCLL real-world registry","author":"Barrientos","year":"2021"},{"key":"10.1016\/j.clml.2024.05.009_bib0024","series-title":"Presented at: 2021 ASH Meeting and Exposition","article-title":"Real-world testing patterns for risk assessment and implications on the adoption of novel therapeutics in chronic lymphocytic leukemia: IGHV mutation status, FISH cytogenetic, and immunophenotyping","author":"Chanan-Khan","year":"2021"},{"key":"10.1016\/j.clml.2024.05.009_bib0025","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1007\/s12325-021-01991-5","article-title":"Real-world clinical outcomes of first-line ibrutinib or chemoimmunotherapy in patients with chronic lymphocytic leukemia by risk status","volume":"39","author":"Huang","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2024.05.009_bib0026","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1182\/bloodadvances.2022008643","article-title":"Racial and socioeconomic disparities in CLL\/SLL: analysis of SEER data from 2006 to 2019","volume":"7","author":"Kittai","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.05.009_bib0027","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1002\/ajh.26937","article-title":"Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia","volume":"98","author":"Vardell","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.05.009_bib0028","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0029","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1002\/cncr.28030","article-title":"Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center","volume":"119","author":"Falchi","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.05.009_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220864","article-title":"Racial\/ethnic, age and sex disparities in leukemia survival among adults in the United States during 1973-2014 period","volume":"14","author":"Utuama","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2024.05.009_bib0031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","article-title":"Racial differences in three major NHL subtypes: descriptive epidemiology","volume":"39","author":"Li","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.clml.2024.05.009_bib0032","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clml.2019.10.009","article-title":"Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry","volume":"20","author":"Mato","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.05.009_bib0033","unstructured":"National Cancer Institute. Cancer stat facts: leukemia \u2014 chronic lymphocytic leukemia (CLL). https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed March 13, 2024."},{"key":"10.1016\/j.clml.2024.05.009_bib0034","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cncr.31738","article-title":"Real-world testing and treatment patterns in chronic lymphocytic leukemia: a SEER patterns of care analysis","volume":"125","author":"Seymour","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.05.009_bib0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clml.2017.11.010","article-title":"Prognostic testing patterns and outcomes of chronic lymphocytic leukemia patients stratified by fluorescence in situ hybridization\/cytogenetics: a real-world clinical experience in the connect CLL registry","volume":"18","author":"Mato","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.05.009_bib0036","first-page":"1266","article-title":"Time to next treatment, health care resource utilization, and costs associated with ibrutinib use among U.S. Veterans with chronic lymphocytic leukemia\/small lymphocytic lymphoma: a real-world retrospective analysis","volume":"26","author":"Huang","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2024.05.009_bib0037","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","article-title":"Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy","volume":"19","author":"Emond","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.05.009_bib0038","article-title":"Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.009_bib0039","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ajh.25261","article-title":"Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial","volume":"93","author":"Mato","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.05.009_bib0040","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1182\/blood-2022-163257","article-title":"Initiating first-line (1L) ibrutinib (Ibr) in patients (pts) with chronic lymphocytic leukemia (CLL) improves overall survival (OS) outcomes to rates approximating an age-matched population of \u226565 years","volume":"140","author":"Ghia","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.009_bib0041","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/cam4.2268","article-title":"Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States","volume":"8","author":"Kabadi","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0042","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cam4.3855","article-title":"Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: real-world evidence from the medicare population","volume":"10","author":"Goyal","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2024.05.009_bib0043","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/bloodadvances.2019001145","article-title":"The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites","volume":"4","author":"Mato","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.05.009_bib0044","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2024.05.009_bib0045","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1080\/10428194.2021.1876863","article-title":"Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System","volume":"62","author":"Frei","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.05.009_bib0046","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ajh.24374","article-title":"Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia","volume":"91","author":"Nabhan","year":"2016","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:28:03Z","timestamp":1724459283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2152265024001800"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}